

Public Health Service





Food and Drug Administration Rockville MD 20857

Re: OP-1 Implant Docket No. 02E-0147

The Honorable James. E. Rogan
Under Secretary of Commerce for Intellectual Property and
Director of the United States Patent and Trademark Office
Box Pat. Ext.

P.O. Box 2327

NOV 0 5 2002

OCT 3 1 2002

**OFFICE OF PETITIONS** 

Dear Director Rogan:

Arlington, VA 22202

This is in regard to the application for patent term extension for U.S. Patent No. 5,258,494 filed by Stryker Corporation under 35 U.S.C. § 156. The medical device claimed by the patent is OP-1 Implant (recombitant human ostogenic protein-1 & bovine bone derived collagen), which was assigned investigational device exemption (IDE) No. HO10002/A01.

A review of the Food and Drug Administration's official records indicates that this product was subject to a regulatory review period before its commercial marketing or use, as required under 35 U.S.C. § 156(a)(4). Our records also indicate that it represents the first permitted commercial marketing or use of the product, as defined under 35 U.S.C. § 156(f)(1), and interpreted by the courts in Glaxo Operations UK Ltd. v. Quigg, 706 F. Supp. 1224 (E.D. Va. 1989), aff'd, 894 F. 2d 392 (Fed. Cir. 1990).

The IDE was approved on October 17, 2001, which makes the submission of the patent term extension application on December 14, 2001, timely within the meaning of 35 U.S.C. § 156(d)(1).

Should you conclude that the subject patent is eligible for patent term extension, please advise us accordingly. As required by 35 U.S.C. § 156(d)(2)(A) we will then determine the applicable regulatory review period, publish the determination in the *Federal Register*, and notify you of our determination.

Please let me know if we can be of further assistance.

Sincerely yours,

Jane A. Axelrad

Associate Director for Policy

Center for Drug Evaluation and Research

cc: James F. Haley, Jr.
Fish & Neave
1251 Avenue of the Americas
New York, NY 10020-1104